| Ashley Powell, DO | |
|
714 Lincoln St Ne, Le Mars, IA 51031-3314 | |
| (712) 546-3620 | |
| (712) 546-3629 |
| Full Name | Ashley Powell |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 714 Lincoln St Ne, Le Mars, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265811038 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DO-04999 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Floyd Valley Healthcare | Le mars, IA | Hospital |
| Good Samaritan Society - Lemars | Le mars, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Floyd Valley Healthcare | 2769385475 | 22 |
News Archive
A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.
Married women are more likely to have sexual difficulties than either single women or married men, suggest the findings of a national survey in Sexually Transmitted Infections.
A firm reassurance that training places for future GPs will be resourced was given today (22/09/04) by English Health Minister John Hutton speaking at a GP Recruitment conference at the BMA.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.
› Verified 9 days ago
| Entity Name | Floyd Valley Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578625653 PECOS PAC ID: 2769385475 Enrollment ID: O20040129001169 |
News Archive
A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.
Married women are more likely to have sexual difficulties than either single women or married men, suggest the findings of a national survey in Sexually Transmitted Infections.
A firm reassurance that training places for future GPs will be resourced was given today (22/09/04) by English Health Minister John Hutton speaking at a GP Recruitment conference at the BMA.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Powell, DO 714 Lincoln St Ne, Le Mars, IA 51031-3314 Ph: (712) 540-3187 | Ashley Powell, DO 714 Lincoln St Ne, Le Mars, IA 51031-3314 Ph: (712) 546-3620 |
News Archive
A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.
Married women are more likely to have sexual difficulties than either single women or married men, suggest the findings of a national survey in Sexually Transmitted Infections.
A firm reassurance that training places for future GPs will be resourced was given today (22/09/04) by English Health Minister John Hutton speaking at a GP Recruitment conference at the BMA.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.
› Verified 9 days ago
Dr. Sheila Rae Holcomb, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 714 Lincoln St Ne, Le Mars, IA 51031 Phone: 712-546-3630 Fax: 712-546-3634 | |
Dr. Steven Joseph Meis, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 714 Lincoln St Ne, Le Mars, IA 51031 Phone: 712-546-3660 Fax: 712-546-3664 | |
Destiny M Miller-mancuso, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 714 Lincoln St. Ne, Le Mars, IA 51031 Phone: 712-546-3492 Fax: 712-546-3352 | |
Cynthia K. Wolff, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 714 Lincoln St Ne, Le Mars, IA 51031 Phone: 712-546-3665 Fax: 712-546-3352 | |
Andrew J Geha, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 714 Lincoln St Ne, Le Mars, IA 51031 Phone: 712-546-3680 Fax: 712-546-3684 | |
Maria E Catalan-aquino, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 194 6th Ave Ne, Le Mars, IA 51031 Phone: 712-546-3630 Fax: 712-546-3694 |